

**DOCKET NO.: ALLE0041-100**  
**(17672 BOT)**  
**Serial No. 10/814,764**

**PATENT**

**In the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method for treating a pressure sore, the method comprising the step of locally administering a therapeutically effective amount of a botulinum toxin to or to the vicinity of a pressure sore of a patient without reducing spasticity of substantially paralyzing a muscle, thereby treating a pressure sore.
2. (original) The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
3. (original) The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.
4. (original) The method of claim 1, wherein the botulinum toxin is administered in an amount of between about 1 unit and about 3,000 units.
5. (original) The method of claim 1, wherein the administration is by topical or subcutaneous administration of the botulinum toxin.
6. (currently amended) A method for treating a pressure sore, the method comprising the step of locally administering a therapeutically effective amount of a botulinum toxin to a pressure sore or to the vicinity of a pressure sore of a patient without reducing spasticity of substantially paralyzing a muscle, thereby treating the pressure sore by facilitating healing of the pressure sore.

DOCKET NO.: ALLE0041-100  
(17672 BOT)  
Serial No. 10/814,764

PATENT

7. (currently amended) A method for preventing development of a pressure sore, the method comprising the step of locally administering a therapeutically effective amount of a botulinum toxin to or to the vicinity of a pressure point of a patient without reducing spasticity of substantially paralyzing a muscle, thereby preventing development of a pressure sore.
8. (original) The method of claim 7, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
9. (original) The method of claim 7, wherein the botulinum toxin is a botulinum toxin type A.
10. (original) The method of claim 7, wherein the botulinum toxin is administered in an amount of between about 5 units and about 25,000 units.
11. (previously presented) The method of claim 7, wherein the administration is by topical or subcutaneous administration of the botulinum toxin.
12. (canceled)
13. (currently amended) A method for treating a pressure sore, the method comprises the step of locally administering a therapeutically effective amount of a botulinum toxin type A to a pressure sore without reducing spasticity of substantially paralyzing a muscle, thereby treating the pressure sore.
14. (previously presented) The method of claim 1, wherein the pressure sore is a result of immobility of the patient.

**DOCKET NO.: ALLE0041-100**  
**(17672 BOT)**  
**Serial No. 10/814,764**

**PATENT**

15. (new) A method for treating a pressure sore that is not related to contractures or spasticity, the method comprising the step of locally administering a therapeutically effective amount of a botulinum toxin to or to the vicinity of a pressure sore of a patient, thereby treating a pressure sore.
16. (new) The method of claim 15, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
17. (new) The method of claim 15, wherein the botulinum toxin is a botulinum toxin type A.
18. (new) The method of claim 15, wherein the botulinum toxin is administered in an amount of between about 1 unit and about 3,000 units.
19. (new) The method of claim 15, wherein the administration is by topical or subcutaneous administration of the botulinum toxin.